4 Best Supplements for Muscle Growth in 2025 - Legal Steroid Alternatives & Bodybuilding Supplements for Bulking and Strength
WOLFSON BRANDS (UK) LIMITED
Glasgow, May 10, 2025 (GLOBE NEWSWIRE) --The best legal supplements for muscle growth is presented by Wolfson Brands
Building serious muscle isn't just about hitting the gym hard, it's about giving your body the right supplements to gain muscle size, recover, and get back training.
In 2025, the supplement game has evolved, offering powerful, legal alternatives to steroids that deliver massive results without the risks.
Whether you're bulking up, shredding, or striving for maximum strength, the right bodybuilding supplements can accelerate your progress and take your gains to the next level and smash plateaus like never before.
Quick comment: There is a lot of information here - to sum up, if you want to pack on the muscle quickly then D-Bal Max is highly recommended. If you want the complete supplement package (Bulking, Cutting, Strength and Recovery) then the Ultimate Legal Steroid Stack is what you need.
These cutting-edge supplements are designed to supercharge protein synthesis, boost testosterone levels, and enhance recovery, all while keeping your gains clean and sustainable.
Perfect for lifters who demand results, these legal steroid alternatives bring elite-level performance to your stack.
Ready to take your training to the next level? Let's break down the 5 best muscle-building supplements of 2025.
Top 4 Best Legal Bodybuilding - Intro
D-Bal Max - Best Supplement for Muscle Growth
CrazyBulk Ultimate Stack - Best Legal Steroid Stack (Bulk and Cut)
CrazyNutrition - Best Mass Gainer Supplement (Protein & Carbs)
Testo Prime - Best Testosterone Booster for Men Over 40
All products are available to order directly from the official website, All supplements are owned by Wolfson Brands (UK) Limited. They offer complimentary shipping to the United States, Canada, and Australia (and many other destinations). There is also a 60 day money back guarantee on all orders.
The Best Supplements for Muscle Growth
Here is a more detailed review of the legal steroid and bodybuilding supplements mentioned above.
1. D-Bal Max - Best Supplement for Muscle Growth> CLICK to view D-Bal Max pricing and special offers
CLICK to see price and options for CrazyBulk legal steroid alternative Stack
CLICK for pricing and special deal on CrazyNutrition Mass Gainer
CLICK to see Testo Prime current price and latest offers <
TestoPrime: The Ultimate Natural Testosterone Booster for Men Over 40
As men hit their 40s and 50s, the natural decline in testosterone can take a toll. From weight gain and reduced muscle mass to low energy, mood swings, and dwindling motivation, these symptoms of low testosterone (Low-T) can feel like your prime years are behind you. But taking TestoPrime supplements helps you reclaim your vitality, rebuild your strength, and feel like your younger self again—all without injections, prescriptions, or harsh chemicals.
Following the powerful muscle-building benefits of D-Bal Max, the all-in-one CrazyBulk Ultimate Stack, and Mass Gainer, TestoPrime is the ultimate solution for older men looking to target the root cause of their struggles: declining testosterone levels.
What Does TestoPrime Do?
TestoPrime is a clinically-backed natural testosterone booster designed to help men over 40 fight back against Low-T and its frustrating side effects. By using 12 natural ingredients, TestoPrime works to:
Increase Natural Testosterone Production: Boost your body's natural T-levels to build lean muscle, burn fat, and restore energy.
Burn Stubborn Fat: Helps convert stored fat into energy, especially around the belly—one of the hardest areas to target.
Improve Strength and Muscle Mass: Supports protein synthesis, giving you the power to rebuild muscle and reclaim your physique.
Boost Energy and Motivation: Say goodbye to fatigue and brain fog with improved mental clarity and physical endurance.
Enhance Mood and Confidence: Reduce stress and enjoy the confidence that comes with feeling strong, energetic, and in control again.
With regular use, TestoPrime supplements helps older men feel stronger, leaner, and more focused, turning back the clock on testosterone decline.
Why Men Over 40 Need TestoPrime
Testosterone production drops naturally with age, beginning in your 30s and declining by 1-2% each year after. By the time you hit your 40s or 50s, symptoms like:
Increased weight gain (especially around the belly)
Reduced muscle mass and strength
Low energy levels
Irritability and mood swings
Decreased sex drive
…can significantly impact your quality of life. TestoPrime provides a natural, safe solution to reverse these effects and help you feel like the best version of yourself again.
What's in the TestoPrime Formula?
TestoPrime's formula is packed with natural, scientifically-proven ingredients that target Low-T symptoms at their core. Some of the highlights include:
D-Aspartic Acid: Stimulates the release of luteinizing hormone, which boosts testosterone production.
Panax Ginseng: A potent antioxidant that revitalizes energy, boosts libido, and combats fatigue.
KSM-66® Ashwagandha: Clinically proven to improve testosterone levels, reduce stress, and support muscle gains.
Fenugreek: Supports metabolism, fat burning, and stamina.
Green Tea Extract: Prevents testosterone breakdown and promotes fat loss.
Zinc and Vitamin D: Essential for maintaining healthy testosterone levels and overall well-being.
Combined with other natural ingredients like garlic extract, pomegranate extract, and vitamins B5 and B6, TestoPrime(backed by Wolfson Brands (UK) Limited) delivers a comprehensive solution for men looking to naturally restore their testosterone.
What Do Older Men Say About TestoPrime?
TestoPrime has been a game-changer for countless men in their 40s, 50s, and beyond:
Matthew Clarke: 'Since taking TestoPrime, I have more energy to play with my kids, I'm less stressed, and I feel happier overall. This supplement is a game-changer.'
Tyler Kaufman: 'At 48, I wanted to get back in shape. After 21 days, I've already noticed significant changes in my strength, size, and energy levels.'
Daniel Ortiz: 'TestoPrime works. My recovery and strength have improved, and I'm much more focused on daily tasks.'
These testimonials reflect TestoPrime's ability to restore energy, strength, and confidence, making it an essential part of any older man's health and fitness routine.
Pros and Cons of TestoPrime
Pros:
Naturally boosts testosterone levels with no synthetic ingredients.
Supports muscle growth, fat loss, and overall energy.
Reduces stress and improves mood.
Clinically-backed ingredients with proven results.
No needles, prescriptions, or cycling required.
Covered by a 60-day money-back guarantee.
Cons:
Requires daily use for best results.
Premium pricing, though the value is undeniable.
Why TestoPrime is the Best Testosterone Booster for Men Over 40
For men in their 40s and 50s, TestoPrime is the ultimate natural solution to combat the effects of Low-T. By restoring your testosterone levels, it helps you build muscle, burn fat, and reclaim your energy and confidence—all without the risks of synthetic alternatives.
Whether you're tired of feeling worn out, frustrated with stubborn weight gain, or simply looking to feel strong and motivated again, TestoPrime is a proven way to turn back the clock.
Order directly from the official website to take advantage of free shipping and a 60-day money-back guarantee. With TestoPrime, your best years are still ahead of you.
Introduction to Muscle Building Supplements
Building muscle isn't just about lifting weights—it's a science. Muscle growth, also known as hypertrophy, occurs when muscles increase in size due to consistent training, proper nutrition, and the right supplements.
This process involves breaking down muscle fibers during workouts and repairing them bigger and stronger with the help of essential nutrients. One key player in this process is essential amino acids, which fuel muscle protein synthesis—the foundation of muscle repair and growth.
For serious lifters, a structured supplement regimen is critical. Protein powders, amino acids, and other targeted supplements can accelerate muscle recovery, improve performance, and lead to significant muscle mass gains over time.
However, it's not a one-size-fits-all approach. Consulting with a healthcare professional ensures you're using the right supplements safely and effectively. By combining smart supplementation with consistent training, you can maximize your muscle-building potential and achieve results faster.
Whether you're a beginner or a seasoned lifter, the right strategy makes all the difference. Pair your workouts with high-quality nutrition and dietary supplements, and watch your progress soar. Muscle growth is attainable—if you commit to the process.
Essential Amino Acids
Essential amino acids (EAAs) are the foundation of muscle cells and repair. They are the building blocks of protein, making them vital for anyone looking to achieve significant muscle gains. Unlike non-essential amino acids, the body cannot produce EAAs naturally—they must come from diet or supplements like whey protein or branched-chain amino acids (BCAAs).
Among the nine essential amino acids, leucine, isoleucine, and valine stand out for their ability to stimulate muscle protein synthesis—the process where muscles rebuild and grow stronger after training. This makes them a popular choice for athletes and serious bodybuilders aiming to maximize recovery and performance.
Studies show that EAAs not only support muscle repair but also enhance strength and athletic performance. Incorporating them into your supplement regimen can give you a competitive edge, helping you recover faster, train harder, and build lean mass more effectively.
How to Choose Supplements for Muscle Gain
Choosing the right muscle-building supplements can make or break your progress. With so many bodybuilding supplement brands on the market, it's essential to evaluate products carefully to ensure they meet your needs. Here's what to consider:
Company Reputation
Always research the brand behind the supplement. Reputable companies are transparent about their ingredients, manufacturing processes, and product testing. Look for brands that use clinically-backed formulas (high quality sources) and manufacture their products in FDA-approved, GMP-certified facilities for safety and quality. Brands with a strong track record in the fitness industry are often the most reliable.
Price and Value
While price shouldn't be the only factor, it's important to find a supplement that offers value for money. Beware of overly cheap options—they may cut corners on quality. Look for products that provide premium ingredients at a reasonable price. Bundles or discounts like 'buy 2, get 1 free' can also help you save.
Money-Back Guarantee
A solid money-back guarantee shows that a company stands by its product. Look for brands that offer at least a 30- or 60-day guarantee, giving you the confidence to try the supplement risk-free.
Customer Reviews
Real user feedback is invaluable. Check for verified reviews on the company's website and third-party platforms. Positive reviews often highlight results like increased muscle mass, faster recovery, and better performance. Negative reviews can alert you to potential issues.
Best Legal Supplements to Gain Muscle Summary
Building muscle doesn't have to mean risking your health with unsafe supplements. Legal supplements like D-Bal Max, CrazyBulk Ultimate Stack, Crazy Nutrition Mass Gainer, and TestoPrime offer safe and effective options to help you achieve your muscle gain targets.
For those looking to boost strength and performance, D-Bal Max is a standout. It's a natural alternative to Dianabol, helping you build lean muscle, improve recovery, and power through tough workouts. If you're aiming for total transformation, the CrazyBulk Ultimate Stack combines several top supplements to enhance muscle growth, burn fat, and increase endurance, making it a favorite for serious lifters.
When it comes to bulking, Crazy Nutrition Mass Gainer delivers the calories and nutrients you need, with 40 grams of protein and 56 grams of clean carbs per serving—without the bloating. And for men over 40, TestoPrime is life-changing, naturally boosting testosterone levels to combat fatigue, weight gain, and low motivation, helping you feel energized and strong again.
While each of these supplements offers unique benefits, D-Bal Max stands out as the best supplement for muscle growth in 2025, combining performance, safety, and results to help you build muscle faster than ever.
Attachment
WOLFSON BRANDS (UK) LIMITED
CONTACT: Contact Info: WOLFSON BRANDS (UK) LIMITED 12 Payne Street Glasgow, G4 0LF United Kingdom Media Contact: Full Name – Daniel Sanchez email: support@dbalmax.com UK: +44 191 743 4476 US: +1 (970) 671-7706
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
an hour ago
- Medscape
Pola-R-GemOx Boosts Survival in R/R DLBCL
MILAN — Combining polatuzumab vedotin (Pola) with rituximab, gemcitabine, and oxaliplatin (R-GemOx) significantly improves survival outcomes in patients with transplant-ineligible, relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), according to new data from the phase 3 POLARGO trial. Presented by Matthew Matasar, MD, chief of the division of blood disorders at Rutgers Cancer Institute, New Brunswick, New Jersey, here at the European Hematology Association (EHA) 2025 Annual Meeting, the study showed a 40% reduction in the relative risk of death with Pola-R-GemOx versus R-GemOx alone. "These are the gems of the congress," said Martin Dreyling, MD, scientific program committee chair for EHA2025, who presided over the session, describing this and similar studies as potentially practice-changing. Improved OS and PFS Matthew Matasar, MD The global trial enrolled 270 patients with R/R DLBCL who were ineligible for autologous stem cell transplant, had received at least one prior line of therapy, and had not previously been treated with Pola. Of those, 255 were randomized 1:1 to receive Pola-R-GemOx or R-GemOx every 21 days for up to 8 cycles. Patients were stratified by age (≤70 vs >70 years), prior lines of therapy (1 vs ≥2), and response to the most recent treatment (relapsed vs refractory). Baseline characteristics were well-balanced between groups; two thirds were treated in the second-line setting and most had refractory disease. At a median follow-up of 24.6 months, the primary endpoint was met: median overall survival (OS) was 19.5 months with Pola-R-GemOx versus 12.5 months with R-GemOx (hazard ratio [HR], 0.60; 95% CI, 0.43-0.83; P = .0017). Two-year OS was 44.0% versus 33.2%, respectively. Progression-free survival (PFS) also significantly improved at a median follow-up of 18.7 months (HR, 0.37; 95% CI, 0.27-0.51; P = .0001), increasing from 2.7 months to 7.4 months. The 12-month PFS was 36.6% for Pola-R-GemOx and 17.9% for R-GemOx. Response rates were nearly double in the experimental group. The overall response rate (ORR) was 52.7% versus 24.6% and the complete response rate was 40.3% versus 19.0%, respectively, as assessed by an independent review committee. Subgroup and Safety Analyses The OS benefit was consistent across subgroups, including those with and without bulky disease, and among both primary refractory and non-refractory patients. Notably, survival benefit was seen in both activated B-cell (ABC) and germinal center B-cell (GCB) subtypes — contrary to prior findings from the POLARIX trial, which had suggested preferential benefit in the ABC subtype. Matasar emphasized the robustness of the results, noting that patients receiving R-GemOx underwent more subsequent lines of therapy, ruling out confounding by post-progression treatment access. However, the enhanced efficacy came with increased toxicity. Patients in the Pola-R-GemOx group received a median of 7.5 cycles versus 4 cycles in the R-GemOx group. Treatment discontinuations due to adverse events (AEs) were more common with Pola-R-GemOx (23.4% vs 8.0%). Grade 3-4 AE rates were similar (57.0% vs 58.4%), though thrombocytopenia and infections were more frequent in the experimental group. Infections were the leading cause of grade 5 AEs, including 10 COVID-related deaths (seven during treatment, three after completion). "It's worth remembering that the study was conducted during the peak of the COVID-19 pandemic," Matasar noted. Peripheral neuropathy, an expected AE due to overlapping neurotoxicities of Pola and oxaliplatin, was observed in 57.0% of patients receiving Pola-R-GemOx versus 28.8% with R-GemOx. Most cases were grade 1, but 3.9% of patients in the experimental group had grade 3 events. "Peripheral neuropathy was not permanent in all patients, approximately half of the patients did experience improvement in neuropathy by the time of study closure, and approximately one third of patients had complete resolution," Matasar reported. A Role in Bridging Therapy? Frank Leebeek, MD, PhD Commenting to Medscape Medical News, Frank Leebeek, MD, PhD, chair of hematology at Erasmus University, Rotterdam, Netherlands, who was not involved in the trial, said: "This is very important. Prognosis remains poor for patients with R/R DLBCL who cannot receive or are ineligible for transplant." He welcomed the new option in the arsenal of treatments for this disease. Concluding his presentation, Matasar stressed the importance of having different tools. "Some patients will be appropriate for CAR-T, some for bispecific antibodies, some will have access to neither and benefit from ADC destination therapy. Pola-R-GemOx represents an alternative treatment option," he said. Leebeek noted that Pola-R-GemOx may serve as a bridge therapy to CAR-T because it does not deplete the T-cell population. "Achieving complete remission after relapse is challenging," he said, "and other regimens can impair the T-cell pool, while this one doesn't." The study was funded by F. Hoffmann-La Roche. Matasar has disclosed financial relationships with ADC Therapeutics, AbbVie, Arvinas, AstraZeneca, Bayer, BMS, Genmab, Ipsen, J&J, Kite, Novartis, Regeneron, Roche, and Pfizer, and research support from Allogene, Arvinas, Bayer, Cellectis, Genentech, J&J, Pfizer, Pharmacyclics, Regeneron, and Roche. He has reported serving as a consultant for AbbVie, Allogene, Arvinas, Bayer, BMS, Genentech, Genmab, Kite, Novartis, Pfizer, and Roche, and being a current equity holder of Merck. Leebeek has reported no relevant financial relationships.
Yahoo
2 hours ago
- Yahoo
Cornish charity boss completes month-long 5k-a-day challenge
A Cornish charity boss has completed a month-long challenge to walk or jog 5k every day. Claire Eldred, director at Dravet Syndrome UK, took part in the #EveryDayinMayForDravet challenge to help raise funds and awareness for the rare form of epilepsy. Dravet Syndrome is a severe neurological condition associated with epilepsy and learning disabilities, affecting one in 15,000 live births in the UK. Lucy Murphy, a young woman who has Dravet Syndrome, and Claire Eldred taking part in the challenge. (Image: supplied) Daily, those with Dravet often endure multiple seizures, and face a significantly higher risk of sudden unexpected death in epilepsy (SUDEP). Clare, who lives in Botallack, West Penwith, said: "I'm very proud to be doing #EveryDayinMayForDravet with and for all the families across the UK who are affected by this devastating, life limiting condition. "Sadly, it's all too common for individuals with Dravet Syndrome to have to wait months or even years to receive a diagnosis as sometimes even medics have not heard of Dravet. "I hope that raising awareness across Cornwall and the Southwest will lead to more families getting an earlier diagnosis and access to the treatment and support that they need." She also highlighted the importance of donations for the charity's continued work. Clare added: "As a small charity, all donations received make a huge difference in helping us to continue our vital work supporting and empowering families, educating professionals, and funding research. "A huge thank you to everyone who is sponsoring me or who is taking part or donating for #EveryDayinMayForDravet." The #EveryDayinMayForDravet challenge saw hundreds of participants across the globe, many of whom committed to 5k or 10k daily efforts. The challenge welcomed all ages and fitness levels, with some children participating in a 2k daily task. This family-friendly initiative is designed to not only raise funds but also to bolster community spirit and inclusivity among supporters. Dravet Syndrome UK continues to serve as a lighthouse for families who struggle with the complex challenges posed by Dravet Syndrome. They aim to ensure those affected receive timely diagnosis, treatment, and the essential support required for improved lives. To sponsor Claire or donate to the cause, visit the charity's JustGiving page. For more information, please visit Dravet Syndrome UK's website.
Yahoo
2 hours ago
- Yahoo
Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study
EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints Dupixent also outperformed Xolair in improving such key signs and symptoms as nasal polyp size and sense of smell in CRSwNP, and lung function and disease control in asthma, with rapid improvements seen as early as 4 weeks Results reinforce the efficacy of Dupixent in treating both upper and lower respiratory diseases by targeting IL-4 and IL-13, two key drivers of type 2 inflammation Paris and Tarrytown, NY, June 15, 2025. Sanofi and Regeneron Pharmaceuticals, Inc. today presented positive results from the EVEREST phase 4 study of adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP) and coexisting asthma. In the study, Dupixent (dupilumab) outperformed Xolair (omalizumab) on all primary and secondary efficacy endpoints of CRSwNP, and in all asthma-related endpoints. The data are from the first-ever presented head-to-head respiratory study with biologic medicines and were shared today in a late-breaking oral presentation at the 2025 European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress, Glasgow, UK. ENT Specialist, Otolaryngology, Head and Neck Surgery, Rhinology, A. Gemelli University Hospital Foundation, IRCSS, Rome, Italy, and lead investigator of the study 'Patients suffering from chronic rhinosinusitis with nasal polyps often live with the constant obstruction of their nasal passages that can lead to burdensome nasal congestion and loss of smell. What's more, a majority of these individuals also have asthma that can substantially impact their quality of life. EVEREST is the first-ever trial to demonstrate the superiority of Dupixent over Xolair on CRSwNP endpoints in patients with coexisting asthma, along with generally similar safety profiles. Together, these Dupixent outcomes provide important insights that will help guide patients and physicians through the treatment decision-making process.' In the EVEREST study, 360 adults with severe, uncontrolled CRSwNP and coexisting asthma were randomized to receive Dupixent 300 mg (n=181) every two weeks or a weight- and immunoglobulin E (IgE) level-based dosing regimen of omalizumab (n=179) every two or four weeks. Both Dupixent and omalizumab were added to background mometasone furoate nasal spray (MFNS). Primary and secondary endpoint results in CRSwNP for patients treated with Dupixent compared to omalizumab at 24 weeks were as follows with differences were seen as early as four weeks: 1.60-point superior reduction in nasal polyp size, a primary endpoint (p<0.00011) 8.0-point superior improvement in ability to identify different smells, a primary endpoint (p<0.00011). More patients on Dupixent improved above the anosmia threshold compared to omalizumab 0.58-point superior reduction in nasal congestion/obstruction, a key secondary endpoint (p<0.00011) 0.81-point superior improvement in loss of smell, a key secondary endpoint (p<0.00011) 1.74-point superior reduction in symptom severity (p<0.00011) 12.7-point difference in health-related quality of life (p<0.00012) 31.27-point difference in peak nasal inspiratory flow (p<0.00012) 1.87 difference in overall severity of rhinosinusitis (p<0.00012) Asthma endpoint results for patients treated with Dupixent compared to omalizumab at 24 weeks were as follows, with differences seen as early as four weeks: 150 mL difference in lung function (pre-bronchodilator FEV1; p=0.0032) 0.48-point difference in asthma control (p<0.00012) The safety results in the EVEREST study were generally consistent with the known safety profile of Dupixent in its approved respiratory indications, with similar overall rates of adverse events (AEs) observed between Dupixent (64%) and omalizumab (67%). Serious AEs were reported in 2% and 4% of patients treated with Dupixent and omalizumab, respectively. Additionally, AEs leading to study discontinuation were reported in 3% of Dupixent patients and 1% of omalizumab patients. About the Dupixent phase 4 studyEVEREST is a randomized, double-blind phase 4 study comparing the efficacy and safety of Dupixent to omalizumab in adults with severe, uncontrolled CRSwNP and coexisting mild, moderate, or severe asthma. During the 24-week study, patients received Dupixent 300 mg every two weeks or omalizumab 75 to 600 mg every two or four weeks, which was added to background MFNS. Omalizumab dosing was determined based on body weight and serum total IgE levels as per the approved label. All endpoints were assessed at 24 weeks. The primary endpoints assessed change from baseline in nasal polyp score (scale: 0-8) and the University of Pennsylvania Smell Identification Test (scale: 0-40). Secondary endpoints included change from baseline in nasal congestion (scale: 0-3), loss of smell (scale: 0-3), total symptom score (scale: 0-9), SNOT-22 (scale: 0-110), peak nasal inspiratory flow, and rhinosinusitis disease severity (visual analogue scale: 0-10 cm). Other endpoints assessed pre-bronchodilator forced expiratory volume over one second and the 7-item Asthma Control Questionnaire (scale: 0-6). About DupixentDupixent (dupilumab) is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL4) and interleukin-13 (IL13) pathways and is not an immunosuppressant. The Dupixent development program has shown significant clinical benefit and a decrease in type 2 inflammation in phase 3 studies, establishing that IL4 and IL13 are two of the key and central drivers of the type 2 inflammation that plays a major role in multiple related and often co-morbid diseases. Dupixent has received regulatory approvals in more than 60 countries in one or more indications including certain patients with atopic dermatitis, asthma, CRSwNP, eosinophilic esophagitis, prurigo nodularis, chronic spontaneous urticaria, and chronic obstructive pulmonary disease in different age populations. More than one million patients are being treated with Dupixent globally. Dupilumab development programDupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement. To date, dupilumab has been studied across more than 60 clinical studies involving more than 10,000 patients with various chronic diseases driven in part by type 2 inflammation. In addition to the currently approved indications, Sanofi and Regeneron are studying dupilumab in a broad range of diseases driven by type 2 inflammation or other allergic processes in phase 3 studies, including chronic pruritus of unknown origin, bullous pemphigoid, and lichen simplex chronicus. These potential uses of dupilumab are currently under clinical investigation, and the safety and efficacy in these conditions have not been fully evaluated by any regulatory authority. About RegeneronRegeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases. For more information, please visit or follow Regeneron on LinkedIn, Instagram, Facebook or X. About Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNYSanofi Media RelationsSandrine Guendoul | +33 6 25 09 14 25 | Berland | +1 215 432 0234 | Le Bourhis | +33 6 75 06 43 81 | Rouault | +33 6 70 93 71 40 | Gilbert | +1 516 521 2929 | Ubaldi | +33 6 30 19 66 46 | Sanofi Investor RelationsThomas Kudsk Larsen |+44 7545 513 693 | Kaisserian | +33 6 47 04 12 11 | Lauscher | +1 908 612 7239 | Browne | +1 781 249 1766 | Pham | +33 7 85 93 30 17 | Elgoutni | +1 617 710 3587 | Châtelet | +33 6 80 80 89 90 | Li | +33 6 84 00 90 72 | Regeneron Media RelationsAnna Hodge | +1 914-255-6475| Regeneron Investor RelationsMark Hudson | +1 914-847-3482 | Sanofi forward-looking statementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking statements are generally identified by the words 'expects', 'anticipates', 'believes', 'intends', 'estimates', 'plans', and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under 'Risk Factors' and 'Cautionary Statement Regarding Forward-Looking Statements' in Sanofi's annual report on Form 20-F for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. All trademarks mentioned in this press release are the property of the Sanofi group except for VelociSuite and Regeneron Genetics Center. Regeneron Forward-Looking Statements and Use of Digital Media This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. ('Regeneron' or the 'Company'), and actual events or results may differ materially from these forward-looking statements. Words such as 'anticipate,' 'expect,' 'intend,' 'plan,' 'believe,' 'seek,' 'estimate,' variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, 'Regeneron's Products') and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, 'Regeneron's Product Candidates') and research and clinical programs now underway or planned, including without limitation Dupixent® (dupilumab) for the treatment of chronic rhinosinusitis with nasal polyps as discussed in this press release; uncertainty of the utilization, market acceptance, and commercial success of Regeneron's Products and Regeneron's Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), including the studies discussed or referenced in this press release, on any of the foregoing; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron's Product Candidates and new indications for Regeneron's Products, such as Dupixent for the treatment of chronic pruritus of unknown origin, bullous pemphigoid, lichen simplex chronicus, and other potential indications; the ability of Regeneron's collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron's Products and Regeneron's Product Candidates; the ability of Regeneron to manage supply chains for multiple products and product candidates and risks associated with tariffs and other trade restrictions; safety issues resulting from the administration of Regeneron's Products (such as Dupixent) and Regeneron's Product Candidates in patients, including serious complications or side effects in connection with the use of Regeneron's Products and Regeneron's Product Candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize Regeneron's Products and Regeneron's Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron's Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement or copay assistance for Regeneron's Products from third-party payors and other third parties, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payors and other third parties and new policies and procedures adopted by such payors and other third parties; changes in laws, regulations, and policies affecting the healthcare industry; competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron's Products and Regeneron's Product Candidates (including biosimilar versions of Regeneron's Products); the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license, collaboration, or supply agreement, including Regeneron's agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics on Regeneron's business; and risks associated with litigation and other proceedings and government investigations relating to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney's Office for the District of Massachusetts), risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA® (aflibercept) Injection), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron's business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron's filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2024, and its Form 10-Q for the quarterly period ended March 31, 2025. Any forward-looking statements are made based on management's current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise. Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website ( and its LinkedIn page ( Xolair® is a registered trademark of Novartis AG. 1 Statistically significant.2Nominally significant as the endpoint was not included in the multiplicity adjustment Press Release
